Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Patients
2.2. Selection Criteria for Primary Debulking Surgery or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery in Our Institute
2.3. Diagnosis of Recurrence
2.4. Chemotherapy and Bevacizumab
2.5. Statistical Analysis
3. Results
3.1. Patient Characteristics
3.2. Bevacizumab Administration
3.3. Survival Analysis
3.4. Bevacizumab-Induced Adverse Events
3.5. Perioperative Complications
3.6. Multivariate Analysis of Prognostic Factors Associated with Progression-Free Survival
4. Discussion
4.1. Key Findings of This Study
4.2. Efficacy of Bev in First-Line Chemotherapy
4.3. Efficacy of Bev in Salvage Chemotherapy
4.4. Efficacy of Aggressive Surgery in CCC
4.5. Strengths and Limitation
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Winter, W.E., 3rd; Maxwell, G.L.; Tian, C.; Carlson, J.W.; Ozols, R.F.; Rose, P.G.; Markman, M.; Armstrong, D.K.; Muggia, F.; McGuire, W.P.; et al. Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study. J. Clin. Oncol. 2007, 25, 3621–3627. [Google Scholar] [CrossRef]
- Sugiyama, T.; Kamura, T.; Kigawa, J.; Terakawa, N.; Kikuchi, Y.; Kita, T.; Suzuki, M.; Sato, I.; Taguchi, K. Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000, 88, 2584–2589. [Google Scholar] [CrossRef]
- del Carmen, M.G.; Birrer, M.; Schorge, J.O. Clear cell carcinoma of the ovary: A review of the literature. Gynecol. Oncol. 2012, 126, 481–490. [Google Scholar] [CrossRef]
- Sugiyama, T.; Okamoto, A.; Enomoto, T.; Hamano, T.; Aotani, E.; Terao, Y.; Suzuki, N.; Mikami, M.; Yaegashi, N.; Kato, K.; et al. Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial. J. Clin. Oncol. 2016, 34, 2881–2887. [Google Scholar] [CrossRef]
- Goff, B.A.; Sainz de la Cuesta, R.; Muntz, H.G.; Fleischhacker, D.; Ek, M.; Rice, L.W.; Nikrui, N.; Tamimi, H.K.; Cain, J.M.; Greer, B.E.; et al. Clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol. Oncol. 1996, 60, 412–417. [Google Scholar] [CrossRef]
- Takano, M.; Sugiyama, T.; Yaegashi, N.; Sagae, S.; Kuzuya, K.; Udagawa, Y.; Tsuda, H.; Suzuki, M.; Kigawa, J.; Goto, T.; et al. Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: A retrospective Japan Clear Cell Carcinoma Study. Int. J. Gynecol. Cancer 2010, 20, 1506–1510. [Google Scholar] [CrossRef] [PubMed]
- Kajiyama, H.; Suzuki, S.; Yoshihara, M.; Nishino, K.; Yoshikawa, N.; Utsumi, F.; Niimi, K.; Mizuno, M.; Kawai, M.; Oguchi, H.; et al. The possible existence of occult metastasis in patients with ovarian clear-cell carcinoma who underwent complete resection without any residual tumours. Oncotarget 2018, 9, 6298–6307. [Google Scholar] [CrossRef] [Green Version]
- Ho, C.M.; Huang, Y.J.; Chen, T.C.; Huang, S.H.; Liu, F.S.; Chang Chien, C.C.; Yu, M.H.; Mao, T.L.; Wang, T.Y.; Hsieh, C.Y. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol. Oncol. 2004, 94, 197–203. [Google Scholar] [CrossRef]
- Burger, R.A.; Brady, M.F.; Bookman, M.A.; Fleming, G.F.; Monk, B.J.; Huang, H.; Mannel, R.S.; Homesley, H.D.; Fowler, J.; Greer, B.E.; et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 2011, 365, 2473–2483. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Perren, T.J.; Swart, A.M.; Pfisterer, J.; Ledermann, J.A.; Pujade-Lauraine, E.; Kristensen, G.; Carey, M.S.; Beale, P.; Cervantes, A.; Kurzeder, C.; et al. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 2011, 365, 2484–2496. [Google Scholar] [CrossRef] [Green Version]
- Gonzalez Martin, A.; Oza, A.M.; Embleton, A.C.; Pfisterer, J.; Ledermann, J.A.; Pujade-Lauraine, E.; Kristensen, G.; Bertrand, M.A.; Beale, P.; Cervantes, A.; et al. Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. Gynecol. Oncol. 2019, 152, 53–60. [Google Scholar] [CrossRef] [Green Version]
- Yagyu, T.; Tsuji, Y.; Haruta, S.; Kitanaka, T.; Yamada, Y.; Kawaguchi, R.; Kanayama, S.; Tanase, Y.; Kurita, N.; Kobayashi, H. Activation of mammalian target of rapamycin in postmenopausal ovarian endometriosis. Int. J. Gynecol. Cancer 2006, 16, 1545–1551. [Google Scholar] [CrossRef]
- Mabuchi, S.; Kawase, C.; Altomare, D.A.; Morishige, K.; Sawada, K.; Hayashi, M.; Tsujimoto, M.; Yamoto, M.; Klein-Szanto, A.J.; Schilder, R.J.; et al. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin. Cancer Res. 2009, 15, 5404–5413. [Google Scholar] [CrossRef] [Green Version]
- Wendel, J.R.H.; Wang, X.; Hawkins, S.M. The Endometriotic Tumor Microenvironment in Ovarian Cancer. Cancers 2018, 10, 261. [Google Scholar] [CrossRef] [Green Version]
- Mabuchi, S.; Kawase, C.; Altomare, D.A.; Morishige, K.; Hayashi, M.; Sawada, K.; Ito, K.; Terai, Y.; Nishio, Y.; Klein-Szanto, A.J.; et al. Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary. Mol. Cancer Ther. 2010, 9, 2411–2422. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bai, H.; Sha, G.; Cao, D.; Yang, J.; Chen, J.; Wang, Y.; Lang, J.; Shen, K.; Zhang, Z. Salvage Chemotherapy for Patients With Recurrent or Persistent Ovarian Clear Cell Carcinoma: A Retrospective Study of 164 Cases. Medicine 2015, 94, e1121. [Google Scholar] [CrossRef] [PubMed]
- Ueda, T.; Tsubamoto, H.; Eguchi, A.; Terada, T.; Shibahara, H. Bevacizumab helped resolve pericardial and pleural effusion that was associated with malignant ovarian clear cell carcinoma. Gynecol. Oncol. Rep. 2016, 16, 11–13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Komiyama, S.; Kato, K.; Inokuchi, Y.; Takano, H.; Matsumoto, T.; Hongo, A.; Asai-Sato, M.; Arakawa, A.; Kamiura, S.; Tabata, T.; et al. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: A prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial). Int. J. Clin. Oncol. 2019, 24, 103–114. [Google Scholar] [CrossRef] [Green Version]
- Itamochi, H.; Kigawa, J.; Terakawa, N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci. 2008, 99, 653–658. [Google Scholar] [CrossRef]
- Takano, M.; Kikuchi, Y.; Yaegashi, N.; Kuzuya, K.; Ueki, M.; Tsuda, H.; Suzuki, M.; Kigawa, J.; Takeuchi, S.; Tsuda, H.; et al. Clear cell carcinoma of the ovary: A retrospective multicentre experience of 254 patients with complete surgical staging. Br. J. Cancer 2006, 94, 1369–1374. [Google Scholar] [CrossRef] [Green Version]
- Tate, S.; Kato, K.; Nishikimi, K.; Matsuoka, A.; Shozu, M. Survival and safety associated with aggressive surgery for stage III/IV epithelial ovarian cancer: A single institution observation study. Gynecol. Oncol. 2017, 147, 73–80. [Google Scholar] [CrossRef]
- Tate, S.; Nishikimi, K.; Matsuoka, A.; Shozu, M. Aggressive surgery for advanced ovarian cancer decreases the risk of intraperitoneal recurrence. Int. J. Clin. Oncol. 2020, 25, 1726–1735. [Google Scholar] [CrossRef]
- Berek, J.S.; Crum, C.; Friedlander, M. Cancer of the ovary, fallopian tube, and peritoneum. Int. J. Gynaecol. Obstet 2015, 131 (Suppl. S2), S111–S122. [Google Scholar] [CrossRef] [Green Version]
- Jacquet, P.; Sugarbaker, P.H. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat. Res. 1996, 82, 359–374. [Google Scholar] [PubMed]
- Aletti, G.D.; Eisenhauer, E.L.; Santillan, A.; Axtell, A.; Aletti, G.; Holschneider, C.; Chi, D.S.; Bristow, R.E.; Cliby, W.A. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol. Oncol. 2011, 120, 23–28. [Google Scholar] [CrossRef] [PubMed]
- Dindo, D.; Demartines, N.; Clavien, P.A. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann. Surg. 2004, 240, 205–213. [Google Scholar] [CrossRef] [PubMed]
- Oza, A.M.; Cook, A.D.; Pfisterer, J.; Embleton, A.; Ledermann, J.A.; Pujade-Lauraine, E.; Kristensen, G.; Carey, M.S.; Beale, P.; Cervantes, A.; et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015, 16, 928–936. [Google Scholar] [CrossRef]
- Aghajanian, C.; Blank, S.V.; Goff, B.A.; Judson, P.L.; Teneriello, M.G.; Husain, A.; Sovak, M.A.; Yi, J.; Nycum, L.R. OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J. Clin. Oncol. 2012, 30, 2039–2045. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Coleman, R.L.; Brady, M.F.; Herzog, T.J.; Sabbatini, P.; Armstrong, D.K.; Walker, J.L.; Kim, B.G.; Fujiwara, K.; Tewari, K.S.; O’Malley, D.M.; et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017, 18, 779–791. [Google Scholar] [CrossRef] [Green Version]
- Pujade-Lauraine, E.; Hilpert, F.; Weber, B.; Reuss, A.; Poveda, A.; Kristensen, G.; Sorio, R.; Vergote, I.; Witteveen, P.; Bamias, A.; et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J. Clin. Oncol. 2014, 32, 1302–1308. [Google Scholar] [CrossRef] [PubMed]
- Gallego, A.; Ramon-Patino, J.; Brenes, J.; Mendiola, M.; Berjon, A.; Casado, G.; Castelo, B.; Espinosa, E.; Hernandez, A.; Hardisson, D.; et al. Bevacizumab in recurrent ovarian cancer: Could it be particularly effective in patients with clear cell carcinoma? Clin. Transl. Oncol. 2020. [Google Scholar] [CrossRef] [PubMed]
- Coleman, R.L.; Spirtos, N.M.; Enserro, D.; Herzog, T.J.; Sabbatini, P.; Armstrong, D.K.; Kim, J.W.; Park, S.Y.; Kim, B.G.; Nam, J.H.; et al. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. N. Engl. J. Med. 2019, 381, 1929–1939. [Google Scholar] [CrossRef] [PubMed]
- Chi, D.S.; Eisenhauer, E.L.; Lang, J.; Huh, J.; Haddad, L.; Abu-Rustum, N.R.; Sonoda, Y.; Levine, D.A.; Hensley, M.; Barakat, R.R. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol. Oncol. 2006, 103, 559–564. [Google Scholar] [CrossRef] [PubMed]
- Wimberger, P.; Lehmann, N.; Kimmig, R.; Burges, A.; Meier, W.; Du Bois, A.; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol. Oncol. 2007, 106, 69–74. [Google Scholar] [CrossRef] [PubMed]
- Chang, S.J.; Bristow, R.E.; Ryu, H.S. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann. Surg. Oncol. 2012, 19, 4059–4067. [Google Scholar] [CrossRef] [PubMed]
Characteristic | Bev− Group (n = 10) | Bev+ Group (n = 18) | p Value | ||
---|---|---|---|---|---|
Age | |||||
Median age, years (IQR) | 54 (48–59) | 53 (46–63) | 0.81 | ||
FIGO Stage, No. (%) | |||||
III | 7 | 70% | 14 | 78% | 0.674 |
IV | 3 | 30% | 4 | 22% | |
Performance status, No. (%) | |||||
0–1 | 9 | 90% | 13 | 72% | 0.375 |
2–4 | 1 | 10% | 5 | 28% | |
CA 125, IU/mL, (median, IQR) | 419 (247–924) | 271 (121–607) | 0.179 | ||
Peritoneal Cancer Index (median, IQR) | 5.5 (3–11.25) | 5.5 (3–17.25) | 0.727 | ||
Timing of debulking surgery | |||||
Primary | 10 | 100% | 11 | 61% | |
Interval | 0 | 0% | 6 | 33% | 0.075 |
No debulking surgery | 0 | 0% | 1 | 6% | |
Surgical complexity score, No. (%) | |||||
Median, IQR | 9 (4.8–11) | 9 (4–14) | 0.7 | ||
Low (0–3) | 1 | 10% | 2 | 11% | |
Moderate (4–7) | 3 | 30% | 7 | 39% | 0.874 |
High (8–18) | 6 | 60% | 9 | 50% | |
Completeness of resection, No. (%) | |||||
0 cm | 9 | 90% | 15 | 83% | |
>0 cm | 1 | 10% | 2 | 11% | 0.742 |
>1 cm | 0 | 1 | 6% | ||
Firstline chemotherapy regimen | |||||
Tri-weekly paclitaxel (or docetaxel) carboplatin | 4 | 40% | 0 | 0% | 0.01 |
Weekly paclitaxel carboplatin | 6 | 60% | 18 | 100% | |
Completeness of firstline chemotherapy, No. (%) | |||||
Completeness | 10 | 100% | 17 | 94% | 1 |
No-completeness | 0 | 1 | 6% |
Adverse Events | Grade | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
0 | 1 | 2 | 3 | 4 | ||||||
Hypertension | 4 | 22% | 4 | 22% | 6 | 33% | 4 | 22% | 0 | |
Proteinuria | 8 | 44% | 5 | 28% | 1 | 6% | 4 | 22% | 0 | |
Bleeding | 12 | 67% | 5 a | 28% | 0 | 1 b | 6% | 0 | ||
Colonic obstruction | 16 | 89% | 0 | 0% | 0 | 2 | 11% | 0 | ||
Thromboemboic events | 18 | 0 | 0 | 0 | 0 | |||||
Gastrointestinal perforation | 18 | 0 | 0 | 0 | 0 | |||||
Wound dehiscence | 18 | 0 | 0 | 0 | 0 | |||||
Fistula | 18 | 0 | 0 | 0 | 0 |
Variable | PFS | OS | |||||
---|---|---|---|---|---|---|---|
Hazard Ratio | 95% CI | p Value | Hazard Ratio | 95% CI | p Value | ||
Performance Status | 0–1/≥2 | 0.28 | 0.09–0.94 | 0.049 | 0.33 | 0.10–1.03 | 0.058 |
Bevacizumab use | Bev +/− | 0.26 | 0.08–0.82 | 0.022 | 0.52 | 0.18–1.46 | 0.216 |
Completeness of resection | Complete/Others | 0.20 | 0.06–0.70 | 0.013 | 0.19 | 0.05–0.78 | 0.021 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tate, S.; Nishikimi, K.; Matsuoka, A.; Otsuka, S.; Shiko, Y.; Ozawa, Y.; Kawasaki, Y.; Shozu, M. Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma. Cancers 2021, 13, 3177. https://doi.org/10.3390/cancers13133177
Tate S, Nishikimi K, Matsuoka A, Otsuka S, Shiko Y, Ozawa Y, Kawasaki Y, Shozu M. Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma. Cancers. 2021; 13(13):3177. https://doi.org/10.3390/cancers13133177
Chicago/Turabian StyleTate, Shinichi, Kyoko Nishikimi, Ayumu Matsuoka, Satoyo Otsuka, Yuki Shiko, Yoshihito Ozawa, Yohei Kawasaki, and Makio Shozu. 2021. "Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma" Cancers 13, no. 13: 3177. https://doi.org/10.3390/cancers13133177